VCEL Q2 2025 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena

VCELVericel Corporation

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$63M+20.1% YoY

Gross Profit

$47M73.7% margin

Operating Income

-$2M-3.2% margin

Net Income

-$553,000-0.9% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+20.2%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$22M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$436M

Total Liabilities

$129M

Stockholders' Equity

$307M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$63M	$53M	+20.1%
Gross Profit	$47M	$37M	+27.4%
Operating Income	-$2M	-$6M	+66.4%
Net Income	-$553,000	-$5M	+88.2%

Revenue Segments

MACI Implants And Kits

$53M100%